Posted in: Modified:
On Friday, France recommended that people who have already recovered from Covid-19 receive a single dose of vaccine, becoming the first country to give such advice.
The three Covid-19 vaccines approved for use in the European Union are given in two doses distributed several weeks apart.
This is because clinical trials showed that immunity to the disease was significantly higher after individuals received two shots.
The French public health authority said on Friday, however, that people who had already been infected with Covid-19 developed an immune response similar to that given by a dose of vaccine and that a single dose would probably suffice. single dose after infection.
“A single dose of vaccine will also play a role in reminding” your immune system how to fight Covid-19, he said.
The authority recommended a gap of three to six months after infection before people who had recovered from Covid-19 received a punch.
“So far, no country has clearly positioned itself in terms of a single dose of vaccination for people who have already contracted Covid-19,” he said.
The vaccination program is still beginning
France has accelerated its vaccination program in recent weeks, but is still in its infancy.
As of Thursday, more than 2.1 million people had received at least one dose of vaccine, and nearly 535,800 had already received two.
At least 3.4 million people have confirmed Covid-19 infections in France, although the relative lack of accessible evidence during the first wave of the pandemic is likely to have been much more addressed.
Two recent studies in the United States suggest that a single dose of vaccine may work in people who have already recovered from Covid-19.
One document said that immunity in people who had had Covid-19 and then received a single dose of vaccine “is equal to or even exceeds” that of people who have not had Covid-19 but who received two doses of vaccine.
A vaccine that is still in development Johnson & Johnson works with a single dose, but has not yet received emergency use authorization from EU and U.S. regulators.
(AFP)